Pure Global AI
NCT06356597Recruiting

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Division of Gastroenterology and Hepatology,Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Jing-yuan Fang, MD, Ph. DPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Colorectal Cancer
Drug/Device/Intervention
Tislelizumab with Fruquintinib, Metronidazole
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jing-yuan Fang, MD, Ph. D
Funder
Shanghai Jiao Tong University School of Medicine
Location
Shanghai,Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
Apr 01, 2024
End date
Dec 12, 2027
Enrollment
25 participants
Primary outcome

objective response rate

Summary

The aim of this study is to evaluate the efficacy and safety of Tislelizumab with
 Fruquintinib, Metronidazole treatment in MSS/MSI-L advanced colorectal cancer patients with
 high abundance of Fusobacterium nucleatum in a single arm Phase II clinical.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Descending colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06356597
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06356597 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jing-yuan Fang, MD, Ph. D and is currently Recruiting. The study focuses on Colorectal Cancer. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.